Filing Flows › Comparisons › LFVN vs AKBA
Lifevantage vs Akebia Therapeutics: LFVN and AKBA compared
Lifevantage is the larger company: $37.1M of revenue in its latest quarter (Q3 2026) against $36.9M for Akebia Therapeutics (Q3 2026). Lifevantage is growing faster (-22% against -37% a year earlier). Lifevantage is more profitable, with an operating margin of -0.4% against -31.1%.
Where the money goes: LFVN and AKBA
Lifevantage (LFVN) · Q3 2026
Lifevantage, Q3 2026: revenue $37.1M (-22% year over year), operating margin -0.4%, net loss $196K, operating cash flow $533K. The chart follows the revenue to costs, profit and cash.
Akebia Therapeutics (AKBA) · Q3 2026
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
| Lifevantage (LFVN) | Akebia Therapeutics (AKBA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $37.1M | $36.9M |
| Revenue growth, Y/Y | -22% | -37% |
| Operating margin | -0.4% | -31.1% |
| Net earnings | −$196K | −$14.4M |
| Net margin | -0.5% | -38.9% |
| Operating cash flow | $533K | $2.3M |
| Free cash flow | — | $1.6M |
Where the revenue comes from
Lifevantage
- Protandim: $18.0M (48%)
- True Science Product Line: $7.6M (20%)
- Life Vantage Product Line: $4.8M (13%)
- AXIO Product Line: $2.9M (8%)
Akebia Therapeutics
- Product revenue, net: $34.8M (94%)
- License, collaboration and other revenue: $2.1M (6%)
Questions
Which is bigger, Lifevantage or Akebia Therapeutics?
Lifevantage is the larger company: $37.1M of revenue in its latest quarter (Q3 2026) against $36.9M for Akebia Therapeutics (Q3 2026).
Is Lifevantage or Akebia Therapeutics growing faster?
Lifevantage is growing faster (-22% against -37% a year earlier).
Which is more profitable, Lifevantage or Akebia Therapeutics?
Lifevantage is more profitable, with an operating margin of -0.4% against -31.1%.
More: Lifevantage earnings · how Lifevantage makes money · Akebia Therapeutics earnings · how Akebia Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.